Health and Healthcare

Biogen-Idec Earnings Preview (BIIB, DNA)

On Wednesday, we’ll get to see earnings out of Biogen Idec Inc. (NASDAQ: BIIB). The estimates from First Call for the biotech company are $0.80 EPS on $835.16 million in revenues.  Estimates for fiscal 2008 are $3.30 EPS on $3.58 billion in revenues.

Despite this stock having been much higher, analysts have an average price target north of $61.00.  Its hard to blame the analysts for not being more bullish since Biogen failed to attract any serious bidder.  Because of that failed bidding process, we’d throw the chart out the window for any long-term patterns and even for longer-term moving averages.  But on a short-term basis it looks like $55.00 held just about the entire time as support and shares are only about 5% under where they were before the company announced it was under strategic review.  If today’s stock price and options were to remain static, we’d say options traders were braced for a move of up to $1.80 to $2.25 in either direction.  We’ll also get to see if Carl Icahn is having any "company acknowledgment or capitulation" in his quest to add three board members.

Since we saw the numbers out of Genentech (NYSE: DNA) for Rituxan, we already have much of the key data for Biogen-Idec revenues.  The rest will boil down to earnings and expense management, along with any new drug data and guidance.

Biogen Idec Inc.’s 52-week trading range is $42.86 to $84.75.

Jon C. Ogg
February 4, 2008

Are You Still Paying With a Debit Card?

The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.

Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!

Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!

 

Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.

AI Portfolio

Discover Our Top AI Stocks

Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.

You can follow him investing $500,000 of his own money on our top AI stocks for free.